Editas Medicine, Inc. Cash Flow Statement
EDIT|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Editas Medicine, Inc. used $210M in operating cash flow and negative free cash flow of $219M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$237.1M | -$220.4M | -$192.5M | -$116.0M | -$133.7M | -$110.0M | -$120.3M | -$97.2M |
| Depreciation & Amortization | $5.8M | $6.3M | $5.1M | $4.0M | $2.8M | $3.3M | $2.7M | $1.2M |
| Operating Cash Flow | -$210.3M | -$177.3M | -$163.8M | -$179.8M | -$40.7M | -$45.7M | -$9.4M | -$50.2M |
| Capital Expenditures | $8.8M | $4.1M | $8.0M | $7.2M | $6.2M | $4.8M | $2.1M | $3.5M |
| Free Cash Flow | -$219.1M | -$181.5M | -$171.8M | -$187.0M | -$46.8M | -$50.5M | -$11.5M | -$53.7M |
| FCF Margin | -678.1% | -920.6% | -672.5% | -206.1% | -228.1% | -158.0% | -83.6% | -887.8% |